… it a potential target in the treatment of small-cell lung cancer. … in patients with previously
treated small-cell lung cancer showed … previously treated extensive-stage small-cell lung cancer. …

… to 20 percent of patients who were previously treated with platinum-based regimens …
previously treated patients with non–small-cell lung cancer in which 10 percent or more of the cells …

… , an mTOR inhibitor, in previously treated, relapsed small cell lung cancer (SCLC) and
evaluated PI3K/Akt signaling pathway biomarkers utilizing baseline tumor. One partial response …

… previously treated advanced NSCLC. Here, we present the longest follow-up of previously
treated … (19%) in patients with previously treated advanced NSCLC. With a minimum follow-up …

… progressive recurrent small cell lung carcinoma not amenable for … Teniposide in the treatment
of small cell lung cancer. The … in small cell lung cancer relapsing after an initial response to …

… Amrubicin, a new anthracycline agent, and topotecan are both active for previously treated
small-cell lung cancer (SCLC). No comparative study of these agents has been reported. This …

… kinase inhibitor, in patients with pretreated advanced non–small-cell lung cancer (NSCLC). …
Two hundred ten patients with advanced NSCLC who were previously treated with one or …

… shown to play a role in non–small-cell lung cancer (NSCLC) pathogenesis and are associated
… , as well as related tyrosine kinases in patients with previously treated, advanced NSCLC. …

… (Navelbine) in previously treated small cell lung can cer. Eur J Cancer 1993;29:1720-1722. …
vindesine (VDS) in previously un treated stage IIIB or IV non-small cell lung can cer- Interim …

… To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with
advanced non—small-cell lung cancer (NSCLC) previously treated with chemotherapy. …